MedTrace Logo

Single-Dose Safety Study of APD791 in Healthy Volunteers

NCT00529646 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2008-12-30

No results posted yet for this study

Summary

The APD791-001 study is designed primarily to evaluate the safety and tolerability of APD791 when administered as a single oral dose to healthy adult subjects.

Conditions

  • Healthy

Interventions

DRUG

APD791

Sponsors & Collaborators

  • Arena Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Christen Anderson, MD, PhD · Arena Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00529646 on ClinicalTrials.gov